Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
194M
-
Number of holders
-
302
-
Total 13F shares, excl. options
-
185M
-
Shares change
-
+8.43M
-
Total reported value, excl. options
-
$6.41B
-
Value change
-
+$325M
-
Put/Call ratio
-
0.16
-
Number of buys
-
187
-
Number of sells
-
-107
-
Price
-
$34.57
Significant Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) as of Q1 2025
388 filings reported holding BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share as of Q1 2025.
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) has 302 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 185M shares
of 194M outstanding shares and own 95.53% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (22.1M shares), Kohlberg Kravis Roberts & Co. L.P. (19.3M shares), VANGUARD GROUP INC (14.9M shares), BlackRock, Inc. (13.4M shares), JANUS HENDERSON GROUP PLC (7.17M shares), Aisling Capital Management LP (6.07M shares), STATE STREET CORP (5.75M shares), FARALLON CAPITAL MANAGEMENT LLC (5.73M shares), Capital Research Global Investors (4.67M shares), and Frazier Life Sciences Management, L.P. (3.8M shares).
This table shows the top 302 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.